Preferred Label : Allogeneic Anti-BCMA CAR T Cells ALLO-605;
NCIt synonyms : Allogeneic Anti-BCMA CAR-T Cells ALLO-605; Allogeneic Anti-BCMA TRAC/CD52-edited CAR T Cells ALLO-605; Allogeneic BCMA TurboCAR T Cells ALLO-605;
NCIt definition : A preparation of allogeneic, transcription activator-like effector nuclease (TALEN)-engineered,
gene-edited T-lymphocytes that have been transduced with a lentiviral vector expressing
a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA)
B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member
17; TNFRSF17) and engineered to express a constitutively active chimeric cytokine
receptor (CACCR), with potential immunostimulating and antineoplastic activities.
Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and CD52 genes
are inactivated. Upon administration, the allogeneic anti-BCMA CAR T Cells ALLO-605
specifically recognize and induce selective toxicity in BCMA-expressing tumor cells.
BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating
factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF).
BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma
cells and plays a key role in plasma cell proliferation and survival. Inactivation
of the CD52 gene makes the modified donor T-cells resistant to an anti-CD52 monoclonal
antibody treatment, that is used during lymphodepletion. The knockout of TRAC eliminates
TCR expression and is intended to abrogate the potential induction of graft-versus-host
disease (GvHD) by the donor T-cells. The expression of CACCR allows for intracellular
cytokine activation signaling, which may enhance expansion and persistence of the
CAR T cells, thereby improving long-term anti-tumor activity. In addition, the incorporated
CD20-based off-switch of ALLO-605 permits selective depletion of the ALLO-605 cells
when the anti-CD20 monoclonal antibody rituximab is administered. ALLO-605 can also
be inactivated with dasatinib.;
Molecule name : ALLO 605; ALLO-605;
NCI Metathesaurus CUI : CL1770673;
Origin ID : C182066;
UMLS CUI : C5666873;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
